15.94% to Target, Numis Reiterates “Buy” Rating for Alliance Pharma PLC (LON:APH) Stock; ACURA PHARMACEUTICALS (ACUR) Shorts Raised By 4.12%

Alliance Pharma plc (LON:APH) Logo

ACURA PHARMACEUTICALS INC (OTCMKTS:ACUR) had an increase of 4.12% in short interest. ACUR’s SI was 20,200 shares in April as released by FINRA. Its up 4.12% from 19,400 shares previously. With 16,900 avg volume, 1 days are for ACURA PHARMACEUTICALS INC (OTCMKTS:ACUR)’s short sellers to cover ACUR’s short positions. The SI to ACURA PHARMACEUTICALS INC’s float is 0.28%. The stock decreased 7.87% or $0.0359 during the last trading session, reaching $0.4201. About shares traded. Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

In an analyst report issued to clients and investors on 17 April, Alliance Pharma PLC (LON:APH) stock “Buy” was kept at Numis. They currently have a GBX 88.00 target price on the stock. Numis’s target price would indicate a potential upside of 15.94% from the company’s current stock price.

The stock decreased 1.50% or GBX 1.15 during the last trading session, reaching GBX 75.45. About 40,291 shares traded. Alliance Pharma plc (LON:APH) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Since October 27, 2017, it had 0 insider buys, and 3 insider sales for $27.46 million activity. On Friday, February 2 the insider D’AMICO LANCE E sold $920,699. Another trade for 220,000 shares valued at $18.94M was made by NORWITT RICHARD ADAM on Monday, October 30. $7.60M worth of stock was sold by Gavelle Jean-Luc on Friday, October 27.

Alliance Pharma plc operates as a specialty pharmaceutical firm in Europe and internationally. The company has market cap of 358.46 million GBP. It acquires the rights to established products, and owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has a 12.57 P/E ratio. The firm provides prescription only medicines, over the counter medications, cosmetics, and nutritional supplements, as well as medical devices.

Analysts await Alliance Pharma plc (LON:APH) to report earnings on April, 25 before the open. They expect $0.80 earnings per share, up 12.68% or $0.09 from last year’s $0.71 per share. APH’s profit will be $3.80 million for 23.58 P/E if the $0.80 EPS becomes a reality. After $0.86 actual earnings per share reported by Alliance Pharma plc for the previous quarter, Wall Street now forecasts -6.98% negative EPS growth.

Investors sentiment decreased to 0.91 in Q4 2017. Its down 0.04, from 0.95 in 2017Q3. It dropped, as 25 investors sold Alliance Pharma plc shares while 209 reduced holdings. 53 funds opened positions while 159 raised stakes. 289.04 million shares or 1.12% less from 292.31 million shares in 2017Q3 were reported. Pennsylvania-based Veritable Limited Partnership has invested 0.03% in Alliance Pharma plc (LON:APH). Silvercrest Asset Management Ltd Co reported 0.01% of its portfolio in Alliance Pharma plc (LON:APH). Moreover, Kbc Gp Inc Nv has 0.02% invested in Alliance Pharma plc (LON:APH). Mitsubishi Ufj & Bk accumulated 710,952 shares. Bingham Osborn & Scarborough Ltd Llc has 2.62% invested in Alliance Pharma plc (LON:APH). Manchester Mngmt Lc holds 1,470 shares. 26,995 are held by Panagora Asset. Hillsdale Mngmt holds 55 shares. Lpl Financial Ltd Com holds 29,015 shares or 0.01% of its portfolio. Citigroup invested in 70,797 shares or 0% of the stock. San Francisco Sentry Inv Grp Inc (Ca) owns 314 shares for 0.01% of their portfolio. Davis R M reported 525,278 shares. Balyasny Asset Mngmt Ltd Liability Company has 211,010 shares for 0.06% of their portfolio. Franklin Resources invested in 1.22M shares or 0.05% of the stock. Ontario Teachers Pension Plan Board owns 124,279 shares or 0.13% of their US portfolio.

Among 4 analysts covering Alliance Pharma PLC (LON:APH), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Alliance Pharma PLC has GBX 80 highest and GBX 52 lowest target. GBX 69.67’s average target is -7.66% below currents GBX 75.45 stock price. Alliance Pharma PLC had 24 analyst reports since September 9, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, August 24 by FinnCap. Numis Securities maintained the stock with “Buy” rating in Wednesday, September 13 report. FinnCap maintained Alliance Pharma plc (LON:APH) rating on Tuesday, December 12. FinnCap has “Buy” rating and GBX 70 target. The rating was initiated by Investec on Wednesday, September 13 with “Buy”. The stock of Alliance Pharma plc (LON:APH) earned “Buy” rating by FinnCap on Tuesday, May 30. The company was maintained on Thursday, November 5 by Numis Securities. The company was maintained on Thursday, September 14 by FinnCap. The firm earned “Buy” rating on Thursday, January 21 by Numis Securities. The stock of Alliance Pharma plc (LON:APH) earned “Buy” rating by Numis Securities on Friday, June 24. Numis Securities maintained the shares of APH in report on Wednesday, September 14 with “Buy” rating.

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. The company has market cap of $8.74 million. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. It currently has negative earnings. The firm has six additional opioid products in various stages of formulation development.